{"name":"Savient Pharmaceuticals","slug":"savient-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"Savient Pharmaceuticals was a New Jersey–based biopharmaceutical company. Its lead product, pegloticase, was a biologic drug for treatment resistant chronic gout, which it marketed beginning in 2011. It also marketed oxandrolone beginning in 1995.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":18023000,"revenueGrowth":264.3,"grossMargin":0,"rdSpend":26238000,"netIncome":-118312000,"cash":119206000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2012"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Puricase","genericName":"Puricase","slug":"puricase","indication":"Other","status":"phase_2"},{"name":"prosaptide","genericName":"prosaptide","slug":"prosaptide","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Puricase","genericName":"Puricase","slug":"puricase","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"prosaptide","genericName":"prosaptide","slug":"prosaptide","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQMFZ2T3dkdDBsWm5DeFZHQ1ZKWEs0MFEwN2ZpMkhjeWlqT1FBbC1lbjRTUmlhdWxmWHdmRW1Ra3FGSko4cjhXUEx6UnJKbHA0c1ZiQWlLS0dVXzA4UTExRVF6VzNFSmg5RkU1a2dYSjNmT21PSVdVU3FURU1LbmJzb25yOW9Xa3JTRW42QXIyRE5yR2tW?oc=5","date":"2023-04-13","type":"pipeline","source":"KFF Health News","summary":"The Drug Company That Prospered Without Creating Any Drugs - KFF Health News","headline":"The Drug Company That Prospered Without Creating Any Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPX0RfVzBoTXFYbXYycnBnSG5GRGFab1FTLXF6NjdaU0h6RmJBTWtrUmozZUFZbFBoSjBJa2UyN2R1b010RHNGZ1RjZ1VXemlZeWN5TDZ5QTh3dDdhSHhmTjlfb3pPbTNpVVkxb0sydE5sM1JtLWNjc3pVd3RJWms5WFphdjd3b3RnVzREZ2tKRUxxbUU4bl92dVpReTQ2bnVBNHJib0Y5b9IBrAFBVV95cUxQZC1rRFo4U3lrdnFoZmJrSUIyc3BfZWZBNnpLZ05kUFZ0RU1adU5MOHZWckhXVGdkMWFQaFVkWFZ6eWRpcEdTS2R4NUtRMUc3TmhwS0xHdkR0VVFQYVFSeUg0S1diM2h5bVlKMVZ0SzBMZTNmVE85bzRpSVJCcTQ1S3RRM2hzZkQwVWhqTm55RFhfZDNhMVFJTXZxSFR0SGdkVVgwT2YzNWtVUDRz?oc=5","date":"2016-11-04","type":"deal","source":"Gulf Times","summary":"Private equity boom brings ‘buy and flip’ mentality to drug prices| Gulf Times - Gulf Times","headline":"Private equity boom brings ‘buy and flip’ mentality to drug prices| Gulf Times","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNYnpVMEJrNDFOWGRKbnVVS2VrQTdhM3BSSVNmMEVuYURua0RjUUdNb0trWlNqelpwaVQtZEpzNmQtcUszRy00dlJLRXdid005Q1lZYjlvTkhfaTh4Y1B6VGtucVgtTVFPQWlaOG5HcWVSWURaSktBTkRUakJudElBOHlad1UwY1R1NHFiUGVqZDU4VFlhOGx0dkJYSQ?oc=5","date":"2015-12-11","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Horizon Pharma Buys Crealta Holdings for $510M - Genetic Engineering and Biotechnology News","headline":"Horizon Pharma Buys Crealta Holdings for $510M","sentiment":"neutral"},{"date":"2014-05-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2014-05-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2014-04-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2014-03-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2014-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2014-02-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2014-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5FWFNHbXBTRV8wU0xZQUktOEU1TlBTYzZPSG1ud0pJd0VwalNKYXhUVkh5VUVyOTdVX2ZIYVlYR0t3bjA1cHFvNUgzeWdFak50TnBOWGlVWXhrdzBYS1ljRDE5Znc1dG9mOWtjT1QwZ25HUVpkSko4UGFqSGtkMjA?oc=5","date":"2014-01-27","type":"pipeline","source":"Pharmafile","summary":"PTC Therapeutics makes series of changes - Pharmafile","headline":"PTC Therapeutics makes series of changes","sentiment":"neutral"},{"date":"2014-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2014-01-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2014-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2013-12-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"discontinued":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":18023000,"revenuePeriod":"2012-12-31","revenueHistory":[{"value":18023000,"period":"2012-12-31"},{"value":4947000,"period":"2012-12-31"},{"value":4916000,"period":"2012-09-30"},{"value":4626000,"period":"2012-06-30"},{"value":3534000,"period":"2012-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":26238000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-118312000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":119206000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}